Toxicogenomics for the Prediction of Toxicity Related to Herbs from Traditional Chinese Medicine

Abstract

Toxicogenomics represents the integration of genomics and toxicology to investigate the interaction between genes and environmental stress in human health. It is a scientific field that studies how the genome is involved in responses to environmental stressors and toxicants. The patterns of altered gene expression that are caused by specific exposures or disease outcomes reveal how toxicants may act and cause disease. Nowadays, toxicogenomics faces great challenges in discriminating the molecular basis of toxicity. We do believe that advances in this field will eventually allow us to describe all the toxicological interactions that occur within a living system. Toxicogenomic responses of a toxic agent in one species (e.g., laboratory animals) may predict the mode of action in another species (e.g., humans) (predictive toxicology). Development and application of toxicogenomic databases and new bioinformatics tools are among the most important aspects of toxicogenomic research which will facilitate sharing and interpretation of the huge amount of biological information generated in this field. Medicinal herbs have played an important role in pharmacy from ancient to modern times. Nowadays, there is a revival of interest in medicinal plants and an increasing scientific interest in bioactive natural products. Medicinal herbs are usually considered to be nontoxic. However, the consumption of herbs could produce prominent toxic effects either due to inherent toxicity or to contaminants (heavy metals, microorganisms, pesticides, toxic organic solvents, radioactivity, etc.). Therefore, a critical assessment of their toxicity is an urgent issue. This review explores the field of toxicogenomics, pinpoints some of its research approaches and describes the challenges it faces. In particular, Chinese herbal preparations have been implicated.

Key words

toxicogenomics - traditional Chinese medicine - microarray - medicinal herbs

References

• 1 Taylor C F. Standards for reporting bioscience data: a forward look.  Drug Discov Today. 2007;  12 527-533
• 2 Efferth T, Li P C, Konkimalla V S, Kaina B. From traditional Chinese medicine to rational cancer therapy.  Trends Mol Med. 2007;  13 353-361
• 3 Nortier J L, Martinez M C, Schmeiser H H, Arlt V M, Bieler C A, Petein M, Depierreux M F, De Pauw L, Abramowicz D, Vereerstraeten P, Vanherweghem J L. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi).  N Engl J Med. 2000;  342 1686-1692
• 4 Arlt V M, Stiborova M, Schmeiser H H. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review.  Mutagenesis. 2002;  17 265-277
• 5 Arlt V M, Alunni-Perret V, Quatrehomme G, Ohayon P, Albano L, Gaid H, Michiels J F, Meyrier A, Cassuto E, Wiessler M, Schmeiser H H, Cosyns J P. Aristolochic acid (AA)-DNA adduct as marker of AA exposure and risk factor for AA nephropathy-associated cancer.  Int J Cancer. 2004;  111 977-980
• 6 Waters M D, Fostel J M. Toxicogenomics and systems toxicology: aims and prospects.  Nat Rev Genet. 2004;  5 936-948
• 7 Mattes W B, Pettit S D, Sansone S A, Bushel P R, Waters M D. Database development in toxicogenomics: issues and efforts.  Environ Health Perspect. 2004;  112 495-505
• 8 Aardema M J, MacGregor J T. Toxicology and genetic toxicology in the new era of “toxicogenomics”: impact of “-omics” technologies.  Mutat Res. 2002;  499 13-25
• 9 Ulrich R, Friend S H. Toxicogenomics and drug discovery: will new technologies help us produce better drugs?.  Nat Rev Drug Discov. 2002;  1 84-88
• 10 Fielden M R, Zacharewski T R. Challenges and limitations of gene expression profiling in mechanistic and predictive toxicology.  Toxicol Sci. 2001;  60 6-10
• 11 Hamadeh H K, Amin R P, Paules R S, Afshari C A. An overview of toxicogenomics.  Curr Issues Mol Biol. 2002;  4 45-56
• 12 Thomas R S, Rank D R, Penn S G, Zastrow G M, Hayes K R, Pande K, Glover E, Silander T, Craven M W, Reddy J K, Jovanovich S B, Bradfield C A. Identification of toxicologically predictive gene sets using cDNA microarrays.  Mol Pharmacol. 2001;  60 1189-1194
• 13 Waters M, Boorman G, Bushel P, Cunningham M, Irwin R, Merrick A, Olden K, Paules R, Selkirk J, Stasiewicz S, Weis B, Van Houten B, Walker N, Tennant R. Systems toxicology and the Chemical Effects in Biological Systems (CEBS) knowledge base.  EHP Toxicogenomics. 2003;  111 15-28
• 14 Merrick B A, Tomer K B. Toxicoproteomics: a parallel approach to identifying biomarkers.  Environ Health Perspect. 2003;  111 A578-A579
• 15 Petricoin E F, Rajapaske V, Herman E H, Arekani A M, Ross S, Johann D, Knapton A, Zhang J, Hitt B A, Conrads T P, Veenstra T D, Liotta L A, Sistare F D. Toxicoproteomics: serum proteomic pattern diagnostics for early detection of drug induced cardiac toxicities and cardioprotection.  Toxicol Pathol. 2004;  32 (Suppl. 1) 122-130
• 16 Wilkins M R, Pasquali C, Appel R D, Ou K, Golaz O, Sanchez J C, Yan J X, Gooley A A, Hughes G, Humphery-Smith I, Williams K L, Hochstrasser D F. From proteins to proteomes: large scale protein identification by two-dimensional electrophoresis and amino acid analysis.  Biotechnology (NY). 1996;  14 61-65
• 17 Youns M, Efferth T, Reichling J, Fellenberg K, Bauer A, Hoheisel J D. Gene expression profiling identifies novel key players involved in the cytotoxic effect of Artesunate on pancreatic cancer cells.  Biochem Pharmacol. 2009;  78 273-283
• 18 Youns M, Fu Y J, Zu Y G, Kramer A, Konkimalla V B, Radlwimmer B, Sultmann H, Efferth T. Sensitivity and resistance towards isoliquiritigenin, doxorubicin and methotrexate in T cell acute lymphoblastic leukaemia cell lines by pharmacogenomics.  Naunyn Schmiedebergs Arch Pharmacol. 2010;  382 221-234
• 19 Pinto-Garcia L, Efferth T, Torres A, Hoheisel J D, Youns M. Berberine inhibits cell growth and mediates caspase-independent cell death in human pancreatic cancer cells.  Planta Med. 2010;  76 1155-1161
• 20 Gomase V S, Tagore S. Toxicogenomics.  Curr Drug Metab. 2008;  9 250-254
• 21 Hamadeh H K, Knight B L, Haugen A C, Sieber S, Amin R P, Bushel P R, Stoll R, Blanchard K, Jayadev S, Tennant R W, Cunningham M L, Afshari C A, Paules R S. Methapyrilene toxicity: anchorage of pathologic observations to gene expression alterations.  Toxicol Pathol. 2002;  30 470-482
• 22 Zweiger G. Knowledge discovery in gene-expression-microarray data: mining the information output of the genome.  Trends Biotechnol. 1999;  17 429-436
• 23 Ahuja Y R, Vijayalakshmi V, Polasa K. Stem cell test: a practical tool in toxicogenomics.  Toxicology. 2007;  231 1-10
• 24 Lewis F, Maughan N J, Smith V, Hillan K, Quirke P. Unlocking the archive–gene expression in paraffin-embedded tissue.  J Pathol. 2001;  195 66-71
• 25 Liu Y M, Sheu S J, Chiou S H, Chang H C, Chen Y P. A comparative study of commercial samples of Ephedrae Herba.  Planta Med. 1993;  59 376-378
• 26 Chuang W C, Lin W C, Sheu S J, Chiou S H, Chang H C, Chen Y P. A comparative study on commercial samples of the roots of Paeonia vitchii and P. lactiflora.  Planta Med. 1996;  62 347-351
• 27 Liu Y M, Sheu S J, Chiou S H, Chang S H, Chen Y P. Capillary electrophoretic analysis of alkaloids in commercial samples of Coptidis Rhizoma.  Phytochem Anal. 1994;  5 256-260
• 28 Chuang W C, Wu H K, Sheu S J, Chiou S H, Chang H C, Chen Y P. A comparative study on commercial samples of Ginseng Radix.  Planta Med. 1995;  61 459-465
• 29 Covey T R, Lee E D, Henion J D. High-speed liquid chromatography/tandem mass spectrometry for the determination of drugs in biological samples.  Anal Chem. 1986;  58 2453-2460
• 30 Han J, Ye M, Xu M, Sun J, Wang B, Guo D. Characterization of flavonoids in the traditional Chinese herbal medicine-Huangqin by liquid chromatography coupled with electrospray ionization mass spectrometry.  J Chromatogr B Anal Technol Biomed Life Sci. 2007;  848 355-362
• 31 Chan K. Some aspects of toxic contaminants in herbal medicines.  Chemosphere. 2003;  52 1361-1371
• 32 Nuwaysir E F, Bittner M, Trent J, Barrett J C, Afshari C A. Microarrays and toxicology: the advent of toxicogenomics.  Mol Carcinog. 1999;  24 153-159
• 33 Heller R A, Schena M, Chai A, Shalon D, Bedilion T, Gilmore J, Woolley D E, Davis R W. Discovery and analysis of inflammatory disease-related genes using cDNA microarrays.  Proc Natl Acad Sci USA. 1997;  94 2150-2155
• 34 Holmes T H, Rahe R H. The Social Readjustment Rating Scale.  J Psychosom Res. 1967;  11 213-218
• 35 Chiu J, Yau T, Epstein R J. Complications of traditional Chinese/herbal medicines (TCM)–a guide for perplexed oncologists and other cancer caregivers.  Support Care Cancer. 2009;  17 231-240
• 36 Yates J S, Mustian K M, Morrow G R, Gillies L J, Padmanaban D, Atkins J N, Issell B, Kirshner J J, Colman L K. Prevalence of complementary and alternative medicine use in cancer patients during treatment.  Support Care Cancer. 2005;  13 806-811
• 37 Boon H S, Olatunde F, Zick S M. Trends in complementary/alternative medicine use by breast cancer survivors: comparing survey data from 1998 and 2005.  BMC Womens Health. 2007;  7 4
• 38 Guo R, Canter P H, Ernst E. A systematic review of randomised clinical trials of individualised herbal medicine in any indication.  Postgrad Med J. 2007;  83 633-637
• 39 McCulloch M, See C, Shu X J, Broffman M, Kramer A, Fan W Y, Gao J, Lieb W, Shieh K, Colford Jr J M. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials.  J Clin Oncol. 2006;  24 419-430
• 40 Senthilnathan P, Padmavathi R, Banu S M, Sakthisekaran D. Enhancement of antitumor effect of paclitaxel in combination with immunomodulatory Withania somnifera on benzo(a)pyrene induced experimental lung cancer.  Chem Biol Interact. 2006;  159 180-185
• 41 Shu X, McCulloch M, Xiao H, Broffman M, Gao J. Chinese herbal medicine and chemotherapy in the treatment of hepatocellular carcinoma: a meta-analysis of randomized controlled trials.  Integr Cancer Ther. 2005;  4 219-229
• 42 Deng G, Cassileth B R, Yeung K S. Complementary therapies for cancer-related symptoms.  J Support Oncol. 2004;  2 419-429
• 43 Cho W C, Chen H Y. Clinical efficacy of traditional Chinese medicine as a concomitant therapy for nasopharyngeal carcinoma: a systematic review and meta-analysis.  Cancer Invest. 2009;  27 334-344
• 44 Yang Y F, Ge J Z, Wu Y, Xu Y, Liang B Y, Luo L, Wu X W, Liu D Q, Zhang X, Song F X, Geng Z Y. Cohort study on the effect of a combined treatment of traditional Chinese medicine and Western medicine on the relapse and metastasis of 222 patients with stage II and III colorectal cancer after radical operation.  Chin J Integr Med. 2008;  14 251-256
• 45 Ernst E. The role of complementary and alternative medicine in cancer.  Lancet Oncol. 2000;  1 176-180
• 46 Kimby C K, Launso L, Henningsen I, Langgaard H. Choice of unconventional treatment by patients with cancer.  J Altern Complement Med. 2003;  9 549-561
• 47 Correa-Velez I, Clavarino A, Eastwood H. Surviving, relieving, repairing, and boosting up: reasons for using complementary/alternative medicine among patients with advanced cancer: a thematic analysis.  J Palliat Med. 2005;  8 953-961
• 48 Gerber B, Scholz C, Reimer T, Briese V, Janni W. Complementary and alternative therapeutic approaches in patients with early breast cancer: a systematic review.  Breast Cancer Res Treat. 2006;  95 199-209
• 49 Shumay D M, Maskarinec G, Kakai H, Gotay C C. Why some cancer patients choose complementary and alternative medicine instead of conventional treatment.  J Fam Pract. 2001;  50 1067
• 50 Nahleh Z, Tabbara I A. Complementary and alternative medicine in breast cancer patients.  Palliat Support Care. 2003;  1 267-273
• 51 Singh H, Maskarinec G, Shumay D M. Understanding the motivation for conventional and complementary/alternative medicine use among men with prostate cancer.  Integr Cancer Ther. 2005;  4 187-194
• 52 White M, Verhoef M. Cancer as part of the journey: the role of spirituality in the decision to decline conventional prostate cancer treatment and to use complementary and alternative medicine.  Integr Cancer Ther. 2006;  5 117-122
• 53 Hlubocky F J, Ratain M J, Wen M, Daugherty C K. Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making.  J Clin Oncol. 2007;  25 548-554
• 54 Efferth T. Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy.  Drug Resist Updat. 2005;  8 85-97
• 55 Efferth T, Olbrich A, Bauer R. mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether.  Biochem Pharmacol. 2002;  64 617-623
• 56 Efferth T, Sauerbrey A, Olbrich A, Gebhart E, Rauch P, Weber H O, Hengstler J G, Halatsch M E, Volm M, Tew K D, Ross D D, Funk J O. Molecular modes of action of artesunate in tumor cell lines.  Mol Pharmacol. 2003;  64 382-394
• 57 Tagliaferri M, Cohen I, Tripathy D. Complementary and alternative medicine in early-stage breast cancer.  Semin Oncol. 2001;  28 121-134
• 58 Zhou S F, Xue C C, Yu X Q, Wang G. Metabolic activation of herbal and dietary constituents and its clinical and toxicological implications: an update.  Curr Drug Metab. 2007;  8 526-553
• 59 Meijerman I, Beijnen J H, Schellens J H. Herb-drug interactions in oncology: focus on mechanisms of induction.  Oncologist. 2006;  11 742-752
• 60 Ernst E, Thompson Coon J. Heavy metals in traditional Chinese medicines: a systematic review.  Clin Pharmacol Ther. 2001;  70 497-504
• 61 Ko R J. Adulterants in Asian patent medicines.  N Engl J Med. 1998;  339 847
• 62 Koh H L, Woo S O. Chinese proprietary medicine in Singapore: regulatory control of toxic heavy metals and undeclared drugs.  Drug Saf. 2000;  23 351-362
• 63 Ernst E. Toxic heavy metals and undeclared drugs in Asian herbal medicines.  Trends Pharmacol Sci. 2002;  23 136-139
• 64 Melchart D, Wagner H, Hager S, Saller R, Ernst E. Quality assurance and evaluation of Chinese medicinal drugs in a hospital of traditional Chinese medicine in Germany: a five-year report.  Altern Ther Health Med. 2001;  7 S24
• 65 Herbette S, Taconnat L, Hugouvieux V, Piette L, Magniette M L, Cuine S, Auroy P, Richaud P, Forestier C, Bourguignon J, Renou J P, Vavasseur A, Leonhardt N. Genome-wide transcriptome profiling of the early cadmium response of Arabidopsis roots and shoots.  Biochimie. 2006;  88 1751-1765
• 66 Koizumi S, Yamada H. DNA microarray analysis of altered gene expression in cadmium-exposed human cells.  J Occup Health. 2003;  45 331-334
• 67 Prpić-Majić D, Pizent A, Jurasović J, Pongracić J, Restek-Samarzija N. Lead poisoning associated with the use of Ayurvedic metal-mineral tonics.  Clin Toxicol. 1996;  34 417-423
• 68 Thatte U M, Rege N N, Phatak S D, Dahanukar S A. The flip side of Ayurveda.  J Postgrad Med. 1993;  39 179-182 182a-182b
• 69 Palchetti I, Mascini M, Minunni M, Bilia A R, Vincieri F F. Disposable electrochemical sensor for rapid determination of heavy metals in herbal drugs.  J Pharm Biomed Anal. 2003;  32 251-256
• 70 Chuang I C, Chen K S, Huang Y L, Lee P N, Lin T H. Determination of trace elements in some natural drugs by atomic absorption spectrometry.  Biol Trace Elem Res. 2000;  76 235-244
• 71 Slifman N R, Obermeyer W R, Aloi B K, Musser S M, Correll Jr W A, Cichowicz S M, Betz J M, Love L A. Contamination of botanical dietary supplements by Digitalis lanata.  N Engl J Med. 1998;  339 806-811
• 72 Halt M. Moulds and mycotoxins in herb tea and medicinal plants.  Eur J Epidemiol. 1998;  14 269-274
• 73 Brandao M G, Freire N, Vianna-Soares C D. [Surveillance of phytotherapeutic drugs in the state of Minas Gerais. Quality assessment of commercial samples of chamomile].  Cad Saude Publica. 1998;  14 613-616
• 74 Cosyns J P, Jadoul M, Squifflet J P, Wese F X, van Ypersele de Strihou C. Urothelial lesions in Chinese herb nephropathy.  Am J Kidney Dis. 1999;  33 1011-1017
• 75 Huang W F, Wen K C, Hsiao M L. Adulteration by synthetic therapeutic substances of traditional Chinese medicines in Taiwan.  J Clin Pharmacol. 1997;  37 344-350
• 76 Keane F M, Munn S E, du Vivier A W, Taylor N F, Higgins E M. Analysis of Chinese herbal creams prescribed for dermatological conditions.  BMJ. 1999;  318 563-564
• 77 Keane F M, Munn S E, Vivier A W, Higgins E M, Taylor N F. Analysis of Chinese herbal creams prescribed for dermatological conditions.  West J Med. 1999;  170 257-259
• 78 Li A M, Chan M H, Leung T F, Cheung R C, Lam C W, Fok T F. Mercury intoxication presenting with tics.  Arch Dis Child. 2000;  83 174-175
• 79 Goudie A M, Kaye J M. Contaminated medication precipitating hypoglycaemia.  Med J Aust. 2001;  175 256-257
• 80 Eisenberg D M, Davis R B, Ettner S L, Appel S, Wilkey S, Van Rompay M, Kessler R C. Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey.  JAMA. 1998;  280 1569-1575
• 81 Ernst E. Possible interactions between synthetic and herbal medicinal products. Part 1: a systematic review of the indirect evidence.  Perfusion. 2000;  13 4-6 8
• 82 Ernst E. Interactions between synthetic and herbal medicinal products. Part 2: a systematic review of the direct evidence.  Perfusion. 2000;  13 60-70
• 83 Mattingly C J, Rosenstein M C, Davis A P, Colby G T, Forrest Jr J N, Boyer J L. The comparative toxicogenomics database: a cross-species resource for building chemical-gene interaction networks.  Toxicol Sci. 2006;  92 587-595
• 84 Wetmore B A, Merrick B A. Toxicoproteomics: proteomics applied to toxicology and pathology.  Toxicol Pathol. 2004;  32 619-642
• 85 Kaput J, Rodriguez R L. Nutritional genomics: the next frontier in the postgenomic era.  Physiol Genomics. 2004;  16 166-177
• 86 Waters M D, Olden K, Tennant R W. Toxicogenomic approach for assessing toxicant-related disease.  Mutat Res. 2003;  544 415-424
• 87 Farland W H. Cancer risk assessment: evolution of the process.  Prev Med. 1996;  25 24-25